查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1572064

青蒿素聯合治療市場：按類型、應用、分銷管道、患者年齡層、劑型、治療類型 - 2025-2030 年全球預測

Artemisinin Combination Therapy Market by Type, Application, Distribution Channel, Patient Age Group, Formulation, Therapy Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

青蒿素聯合治療市場2023年估值為3.4118億美元，預計2024年將達到3.6234億美元，複合年成長率為6.46%，預計到2030年將達到5.2904億美元。

青蒿素聯合治療(ACT) 是一種抗瘧療法，使用青蒿素衍生物與夥伴藥物聯合使用，以提高療效並抑制抗藥性的發展。對 ACT 的需求在於其在快速減少感染瘧疾原蟲的患者體內的寄生蟲載量方面的卓越功效，以及它們在全球抗擊瘧疾努力中的重要作用。最終用途範圍主要是瘧疾流行地區的醫療機構，包括醫院、診所和社區健康計畫。推動市場成長的主要因素包括全球瘧疾負擔的增加、國際衛生組織資金的增加以及政府加強瘧疾控制計畫的努力。由於意識的提高和供應鏈物流的改善促進了農村地區的准入，需求也在增加。然而，市場面臨重大挑戰，包括青蒿素部分抗藥性的出現、聯合治療的高成本以及獲得核准的監管障礙。有機會開發新的藥物配方，並擴大 ACT 與先進診斷工具的使用，以進行有針對性的瘧疾管理。為了抓住這些機會，公司應專注於旨在克服抗藥性和降低成本的研究和創新，包括開發合成衍生物和新型藥物輸送平台。此外，與公共衛生計劃建立夥伴關係可以在傳播和採用方面提供顯著優勢。市場動態複雜，並受到當地疾病發生率、資金籌措水準和法規環境的影響，需要靈活的商務策略來適應不斷變化的條件。在耐受性和成本效益的限制下進行創新至關重要，因此對生物強化學名藥和新興數位健康平台的綜合解決方案的研究可能會帶來重大進展。總體而言，ACT 市場充滿活力但充滿挑戰，需要策略洞察力和創新方法來實現持續成長和影響。

主要市場統計
基準年[2023] 34118萬美元
預測年份 [2024] 3.6234億美元
預測年份 [2030] 52904萬美元
複合年成長率（%） 6.46%

市場動態：快速發展的青蒿素聯合治療市場的關鍵市場洞察

供需的動態交互作用正在改變青蒿素聯合治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 由於瘧疾的傳播，對青蒿素聯合治療的需求增加
    • 政府推動青蒿素聯合療法使用的舉措
    • 提高人們對聯合治療在瘧疾治療中益處的認知
  • 市場限制因素
    • 製造成本高、供應鏈效率低
  • 市場機會
    • 活性化政府和私部門對抗瘧疾藥研究的投資
    • 加強製藥公司和研究機構之間的合作和夥伴關係
  • 市場挑戰
    • 青蒿素聯合治療全球分銷的監管障礙

波特五力策略工具引領青蒿素聯合治療青蒿素

波特的五力架構是了解青蒿素聯合治療市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解青蒿素聯合治療市場的外部影響

外部宏觀環境因素在塑造青蒿素聯合治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解青蒿素聯合治療市場的競爭格局

對青蒿素聯合治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣青蒿素聯合治療市場供應商績效評估

FPNV定位矩陣是評估青蒿素聯合治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製青蒿素聯合治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對青蒿素聯合治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 瘧疾流行增加了對青蒿素聯合治療的需求
      • 政府推動青蒿素聯合治療使用的舉措
      • 提高人們對聯合治療在瘧疾治療中益處的認知
    • 抑制因素
      • 生產成本高、供應鏈效率低下
    • 機會
      • 加強政府和私部門對抗瘧疾藥研究的投資
      • 加強製藥公司和研究機構之間的合作和夥伴關係
    • 任務
      • 青蒿素聯合治療全球分銷的監管障礙
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章青蒿素聯合治療市場：依類型

  • 蒿甲醚-本芴醇
  • 青蒿琥酯阿莫地喹
  • 青蒿琥酯甲氟喹
  • 青蒿酯離胺酸啶
  • 青蒿素-哌喹

第7章青蒿素聯合治療市場：依應用分類

  • 診所
  • 醫院
  • 家庭使用
  • 調查機構

第8章青蒿素聯合治療市場：按分銷管道

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第 9 章依患者年齡層分類的青蒿素聯合治療市場

  • 成人用
  • 老年病
  • 小兒科

第10章 處方青蒿素聯合治療市場

  • 膠囊
  • 注射
  • 暫停
  • 錠劑

第11章依治療類型分類的青蒿素聯合治療市場

  • 聯合治療
  • 一線治療
  • 單一療法
  • 二線治療

第12章 美洲青蒿素聯合治療青蒿素

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區青蒿素聯合治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲青蒿素聯合治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C6291884E

The Artemisinin Combination Therapy Market was valued at USD 341.18 million in 2023, expected to reach USD 362.34 million in 2024, and is projected to grow at a CAGR of 6.46%, to USD 529.04 million by 2030.

Artemisinin Combination Therapy (ACT) is an antimalarial treatment that combines an artemisinin derivative with a partner drug to enhance efficacy and reduce resistance development. The necessity of ACT arises from its superior efficacy in rapidly reducing the parasite biomass in patients infected with Plasmodium falciparum and its critical role in global efforts to combat malaria. The application and end-use scope primarily extend to healthcare settings in malaria-endemic regions, involving hospitals, clinics, and community health programs. Key factors driving market growth include the global malaria burden, increased funding from international health organizations, and government initiatives to enhance malaria control programs. There's also rising demand due to increased awareness and improved supply chain logistics facilitating rural access. However, the market faces significant challenges such as the emergence of partial artemisinin resistance, the high cost of combination therapies, and regulatory hurdles in obtaining approvals. Opportunities exist in the development of newer drug formulations and the expansion of ACT use in combination with advanced diagnostic tools for precise malaria management. To seize these opportunities, companies should focus on research and innovation aimed at overcoming resistance and decreasing costs, such as developing synthetic derivatives or novel drug delivery platforms. Encouraging partnerships with public health initiatives can also provide a substantial advantage in dissemination and adoption. The market dynamics are complex, influenced by geographical disease incidence, funding levels, and regulatory environments, which necessitate agile business strategies to adapt to changing landscapes. Innovating within the constraints of resistance and cost-effectiveness will be crucial; therefore, research on bio-enhanced generics or integrative solutions with emerging digital health platforms could usher in significant advancements. Overall, the ACT market is vibrant yet challenging, requiring strategic insights and innovative approaches for sustained growth and impact.

KEY MARKET STATISTICS
Base Year [2023] USD 341.18 million
Estimated Year [2024] USD 362.34 million
Forecast Year [2030] USD 529.04 million
CAGR (%) 6.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of malaria leading to increased demand for artemisinin combination therapy
    • Government initiatives promoting the use of artemisinin combination treatments
    • Rising awareness about the advantages of combination therapy for malaria treatment
  • Market Restraints
    • High production costs and supply chain inefficiencies
  • Market Opportunities
    • Heightened government and private sector investments in antimalarial drug research
    • Rising collaborations and partnerships between pharmaceutical companies and research institutes
  • Market Challenges
    • Regulatory hurdles related to the global distribution of artemisinin combination therapy

Porter's Five Forces: A Strategic Tool for Navigating the Artemisinin Combination Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artemisinin Combination Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artemisinin Combination Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artemisinin Combination Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artemisinin Combination Therapy Market

A detailed market share analysis in the Artemisinin Combination Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artemisinin Combination Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artemisinin Combination Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artemisinin Combination Therapy Market

A strategic analysis of the Artemisinin Combination Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artemisinin Combination Therapy Market, highlighting leading vendors and their innovative profiles. These include Ajanta Pharma Limited, Aurobindo Pharma Limited, Cipla Limited, Dafra Pharma International NV, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Guilin Pharmaceutical Co., Ltd., Ipca Laboratories Limited, KPC Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer Inc., Ranbaxy Laboratories Limited, Sanofi S.A., Shin Poong Pharmaceutical Co., Ltd., Strides Pharma Science Limited, Sumaya Biotech Pvt. Ltd., Turing Pharmaceuticals AG, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Artemisinin Combination Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Artemether-Lumefantrine, Artesunate-Amodiaquine, Artesunate-Mefloquine, Artesunate-Pyronaridine, and Dihydroartemisinin-Piperaquine.
  • Based on Application, market is studied across Clinic, Hospital, Household, and Research Institute.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Formulation, market is studied across Capsule, Injection, Suspension, and Tablet.
  • Based on Therapy Type, market is studied across Combination Therapy, First-Line Therapy, Mono Therapy, and Second-Line Therapy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of malaria leading to increased demand for artemisinin combination therapy
      • 5.1.1.2. Government initiatives promoting the use of artemisinin combination treatments
      • 5.1.1.3. Rising awareness about the advantages of combination therapy for malaria treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs and supply chain inefficiencies
    • 5.1.3. Opportunities
      • 5.1.3.1. Heightened government and private sector investments in antimalarial drug research
      • 5.1.3.2. Rising collaborations and partnerships between pharmaceutical companies and research institutes
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles related to the global distribution of artemisinin combination therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Artemisinin Combination Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Artemether-Lumefantrine
  • 6.3. Artesunate-Amodiaquine
  • 6.4. Artesunate-Mefloquine
  • 6.5. Artesunate-Pyronaridine
  • 6.6. Dihydroartemisinin-Piperaquine

7. Artemisinin Combination Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Clinic
  • 7.3. Hospital
  • 7.4. Household
  • 7.5. Research Institute

8. Artemisinin Combination Therapy Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies
  • 8.5. Retail Pharmacies

9. Artemisinin Combination Therapy Market, by Patient Age Group

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Artemisinin Combination Therapy Market, by Formulation

  • 10.1. Introduction
  • 10.2. Capsule
  • 10.3. Injection
  • 10.4. Suspension
  • 10.5. Tablet

11. Artemisinin Combination Therapy Market, by Therapy Type

  • 11.1. Introduction
  • 11.2. Combination Therapy
  • 11.3. First-Line Therapy
  • 11.4. Mono Therapy
  • 11.5. Second-Line Therapy

12. Americas Artemisinin Combination Therapy Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Artemisinin Combination Therapy Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Artemisinin Combination Therapy Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. ARTEMISININ COMBINATION THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARTEMISININ COMBINATION THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARTEMISININ COMBINATION THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER-LUMEFANTRINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-AMODIAQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-MEFLOQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-PYRONARIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ-PIPERAQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOUSEHOLD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 288. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2023